These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 22318027)

  • 1. OpenVigil--free eyeballs on AERS pharmacovigilance data.
    Böhm R; Höcker J; Cascorbi I; Herdegen T
    Nat Biotechnol; 2012 Feb; 30(2):137-8. PubMed ID: 22318027
    [No Abstract]   [Full Text] [Related]  

  • 2. OpenVigil FDA - Inspection of U.S. American Adverse Drug Events Pharmacovigilance Data and Novel Clinical Applications.
    Böhm R; von Hehn L; Herdegen T; Klein HJ; Bruhn O; Petri H; Höcker J
    PLoS One; 2016; 11(6):e0157753. PubMed ID: 27326858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More eyeballs on AERS.
    Pratt LA; Danese PN
    Nat Biotechnol; 2009 Jul; 27(7):601-2. PubMed ID: 19587659
    [No Abstract]   [Full Text] [Related]  

  • 4. AERS spider: an online interactive tool to mine statistical associations in Adverse Event Reporting System.
    Grigoriev I; zu Castell W; Tsvetkov P; Antonov AV
    Pharmacoepidemiol Drug Saf; 2014 Aug; 23(8):795-801. PubMed ID: 24677538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse event profiles of platinum agents: data mining of the public version of the FDA adverse event reporting system, AERS, and reproducibility of clinical observations.
    Sakaeda T; Kadoyama K; Okuno Y
    Int J Med Sci; 2011; 8(6):487-91. PubMed ID: 21897761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS.
    Kadoyama K; Kuwahara A; Yamamori M; Brown JB; Sakaeda T; Okuno Y
    J Exp Clin Cancer Res; 2011 Oct; 30(1):93. PubMed ID: 21970649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suboptimal reporting of adverse medical events to the FDA Adverse Events Reporting System by nurse practitioners and physician assistants.
    Ehrenpreis ED; Sifuentes H; Ehrenpreis JE; Smith ZL; Marshall ML
    Expert Opin Drug Saf; 2012 Mar; 11(2):177-83. PubMed ID: 22316142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 150 years of pharmacovigilance.
    Routledge P
    Lancet; 1998 Apr; 351(9110):1200-1. PubMed ID: 9643710
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug-versus-drug adverse event rate comparisons: a pilot study based on data from the US FDA Adverse Event Reporting System.
    Hochberg AM; Pearson RK; O'Hara DJ; Reisinger SJ
    Drug Saf; 2009; 32(2):137-46. PubMed ID: 19236120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An experimental investigation of masking in the US FDA adverse event reporting system database.
    Wang HW; Hochberg AM; Pearson RK; Hauben M
    Drug Saf; 2010 Dec; 33(12):1117-33. PubMed ID: 21077702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective data mining of six products in the US FDA Adverse Event Reporting System: disposition of events identified and impact on product safety profiles.
    Bailey S; Singh A; Azadian R; Huber P; Blum M
    Drug Saf; 2010 Feb; 33(2):139-46. PubMed ID: 20082540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anatomy of Risk Evaluation and Mitigation Strategies (REMS).
    Loeser KK; McKoy JM; Schumock GT
    Cancer Treat Res; 2019; 171():93-105. PubMed ID: 30552659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations.
    Kadoyama K; Miki I; Tamura T; Brown JB; Sakaeda T; Okuno Y
    Int J Med Sci; 2012; 9(1):33-9. PubMed ID: 22211087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
    Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
    Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety profile of drugs for advanced melanoma: A report based on 2008-2018 US Food and Drug Administration Data.
    Casarotto E; Noize P; Létinier L; Salvo F; Pham-Ledard A; Molimard M
    Br J Clin Pharmacol; 2021 Jul; 87(7):2988-2995. PubMed ID: 33294983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platinum agent-induced hypersensitivity reactions: data mining of the public version of the FDA adverse event reporting system, AERS.
    Sakaeda T; Kadoyama K; Yabuuchi H; Niijima S; Seki K; Shiraishi Y; Okuno Y
    Int J Med Sci; 2011; 8(4):332-8. PubMed ID: 21611115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
    Peng L; Xiao K; Ottaviani S; Stebbing J; Wang YJ
    Expert Opin Drug Saf; 2020 Nov; 19(11):1505-1511. PubMed ID: 32693646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns in spontaneous adverse event reporting among branded and generic antiepileptic drugs.
    Bohn J; Kortepeter C; Muñoz M; Simms K; Montenegro S; Dal Pan G
    Clin Pharmacol Ther; 2015 May; 97(5):508-17. PubMed ID: 25670505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leveraging MEDLINE indexing for pharmacovigilance - Inherent limitations and mitigation strategies.
    Winnenburg R; Sorbello A; Ripple A; Harpaz R; Tonning J; Szarfman A; Francis H; Bodenreider O
    J Biomed Inform; 2015 Oct; 57():425-35. PubMed ID: 26342964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.